
Merck has gained access to AiCuris’ portfolio of investigational medicines targeting human cytomegalovirus (HCMV) via a global licensing agreement. It …
Amphista doses first patient in AML trial of protein degrader
Jennings becomes President of Beckman Coulter Diagnostics
Boyds expands Regulatory Affairs team to support growing demand

